Overview

Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Primary Objective: - To assess potential impact of moderate and severe renal impairment on the pharmacokinetics of cabazitaxel Secondary Objective: - To assess the safety of cabazitaxel in patients with various degrees of renal impairment
Phase:
Phase 1
Details
Lead Sponsor:
Sanofi